Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.460 -0.080 (-2.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Mar 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 Next >
News headline image
Bayer and Recursion Focus Research Collaboration on Oncology
Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology... 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio 
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent... 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances... 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Biotech & Healthcare Meet AI: Stocks Soar On Innovation Potential
A growing number of companies in the biotech and healthcare industries are using AI to revolutionize drug discovery and patient care, leading to stock surges. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Exscientia is the Sniper of the AI Drug Discovery Industry
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
Valence Labs is Recursion’s new machine learning research center that aims to promote open science and academic research. $1 million will be committed to advancing the next generation of academic... 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 7/17 - 7/21
Investor sentiment remains strong but upcoming tech earnings and an expected interest rate hike may provide more clarity on the short-term outlook for stocks 
Via MarketBeat
Topics Economy
News headline image
Nvidia Invested $50 million into This AI Drug Discovery Biotech
Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Recursion Pharmaceuticals (NASDAQ: RXRX) Forms Powerful Partnership with NVIDIA (NASDAQ: NVDA)
A $50 Million Investment to Boost AI Capabilities in Drug Discovery Recursion Pharmaceuticals (NASDAQ: RXRX), a trailblazer in TechBio that 
Via Spotlight Growth
Topics Artificial Intelligence
News headline image
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
Companies to collaborate on software for biotech and pharmaceutical companies to create improved patient treatments faster 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored Phase 2 clinical trial for cerebral cavernous malformation (CCM). CCM is a devastating... 
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
From Recursion Pharmaceuticals
Via GlobeNewswire
News headline image
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.